Epidemiology and Survival Determinants of Monomorphic Epitheliotropic T-Cell Lymphoma: A Pooled Patient-Level Dataset Analysis.
A rare aggressive intestinal lymphoma study identifies risk factors and suggests stem cell transplant works best in chemotherapy-responsive patients.
This large pooled retrospective analysis characterizes MEITL—a rare aggressive intestinal T-cell lymphoma—with the largest global dataset to date (n=299), identifying advanced staging, anatomical distribution, and elevated LDH as independent adverse prognostic factors. Exploratory analyses suggest SCT benefit may be concentrated in chemosensitive patients, providing a framework for risk stratification in this high-unmet-need rare lymphoma with no established curative therapy.
What the study was
- Study design
- Pooled retrospective patient-level dataset analysis
- Population
- Adults with MEITL (global cohort, predominantly East Asian)
- Sample size
- 299
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Hematological Oncology
Why it surfaced
Largest pooled analysis of MEITL (n=299); defines prognostic factors in a rare, highly lethal lymphoma with no standard therapy; identifies SCT as potential salvage in chemosensitive subgroup; directly relevant to T1 and T9 watchlist topics.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.